Agilent Technologies, Inc. (A) KPIs and segments
Close on Nov 17, 2026Market cap $48.55BP/E 34.0Yield 0.58%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Agilent Technologies · năm tài chính kết thúc ngày 31 tháng 10
Nhìn nhanh KPI của Agilent Technologies: 43 chỉ số vận hành, trong đó có Core Revenue Growth, Life Sciences & Diagnostics Markets Group (LDG) và Agilent CrossLab Group (ACG), lấy từ 176 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Agilent Technologies kết thúc ngày 31 tháng 10 — Q3 FY26 = CQ2 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 | Q4 FY23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Agilent CrossLab($M)3 | 786 | 759 | 758 | 755 | 744 | 713 | 696 | 706 | 691 | 664 | 686 | 1,492 | |
Americas($M) | 289 | 289 | 273 | 290 | 274 | 270 | 261 | 269 | 267 | 259 | 253 | 536 | |
Asia Pacific($M) | 276 | 248 | 270 | 248 | 258 | 249 | 247 | 247 | 240 | 223 | 248 | 564 | |
Europe($M) | 221 | 222 | 215 | 217 | 212 | 194 | 188 | 190 | 184 | 182 | 185 | 392 | |
Life Sciences and Diagnostics Markets($M)3 | 746 | 732 | 679 | 755 | 670 | 654 | 647 | 657 | 585 | 604 | 620 | ||
Americas($M) | 369 | 363 | 307 | 384 | 316 | 325 | 312 | 316 | 268 | 290 | 283 | ||
Europe($M) | 201 | 214 | 203 | 218 | 201 | 177 | 190 | 186 | 177 | 176 | 184 | ||
Asia Pacific($M) | 176 | 155 | 169 | 153 | 153 | 152 | 145 | 155 | 140 | 138 | 153 | ||
Applied Markets($M)3 | 346 | 344 | 361 | 351 | 324 | 301 | 338 | 338 | 302 | 305 | 352 | ||
Asia Pacific($M) | 161 | 150 | 163 | 158 | 152 | 147 | 157 | 165 | 140 | 149 | 169 | ||
Americas($M) | 103 | 112 | 98 | 102 | 93 | 83 | 96 | 95 | 91 | 88 | 94 | ||
Europe($M) | 82 | 82 | 100 | 91 | 79 | 71 | 85 | 78 | 71 | 68 | 89 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Product($M) | 1,333 | 1,305 | 1,273 | 1,328 | 1,230 | 1,186 | 1,200 | 1,217 | 1,121 | 1,125 | 1,209 | 1,232 | |
Non-Instrumentation and Other($M) | 1,235 | 1,217 | 1,140 | 1,208 | 1,139 | 1,118 | 1,056 | 1,081 | 1,022 | 1,025 | 1,028 | 1,037 | |
Instrumentation($M) | 643 | 618 | 658 | 653 | 599 | 550 | 625 | 620 | 556 | 548 | 630 | 651 | |
Services and Other($M) | 545 | 530 | 525 | 533 | 508 | 482 | 481 | 484 | 457 | 448 | 449 | 456 | |
Americas($M) | 761 | 764 | 678 | 776 | 683 | 678 | 669 | 680 | 626 | 637 | 630 | 702 | |
Asia Pacific($M) | 613 | 553 | 602 | 559 | 563 | 548 | 549 | 567 | 520 | 510 | 570 | 553 | |
Europe($M) | 504 | 518 | 518 | 526 | 492 | 442 | 463 | 454 | 432 | 426 | 458 | 433 | |
Agilent CrossLab($M) | 270 | 242 | 240 | 246 | 248 | 231 | 221 | 239 | 248 | 216 | 222 | 504 | |
Life Sciences and Diagnostics Markets($M) | 176 | 161 | 109 | 172 | 118 | 129 | 117 | 141 | 114 | 115 | 114 | ||
Applied Markets($M) | 86 | 80 | 93 | 87 | 71 | 59 | 84 | 86 | 70 | 64 | 92 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Agilent CrossLab($M) | 448 | 421 | 418 | 415 | 410 | 396 | 390 | ||||||
Life Sciences and Diagnostics Markets($M) | 414 | 395 | 343 | 400 | 338 | 345 | 342 | ||||||
Applied Markets($M) | 198 | 192 | 204 | 192 | 174 | 161 | 188 | ||||||
Product($M) | 774 | 738 | 702 | 741 | 653 | 648 | 665 | 679 | 630 | 644 | 695 | 694 | |
Services and Other($M) | 268 | 252 | 244 | 249 | 235 | 218 | 234 | 237 | 225 | 212 | 213 | 221 | |
Life Sciences and Diagnostics Markets($M) | 5,997 | 5,945 | 5,790 | 5,866 | |||||||||
Agilent CrossLab($M) | 2,427 | 2,435 | 2,421 | 2,360 | 916 | 925 | 947 | 897 | |||||
Applied Markets($M) | 882 | 858 | 873 | 872 | |||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Core Revenue Growth — Constant Currency, Excl. M&A (Headline Exact, % YoY)(%)9 | 7.3% | 6.3% | 4.4% | 7.2% | 6.1% | 5.3% | 1.2% | -0.3% | -4.4% | -7.4% | -6.4% | -9.7% | |
Core Revenue Growth — Reconciliation Table Rounded (% YoY)(%) | 7.0% | 6.0% | 4.0% | 7.0% | 6.0% | 5.0% | 1.0% | -4.0% | -7.0% | -6.0% | -10.0% | ||
GAAP Reported Revenue Growth (Headline Exact, % YoY)(%) | 8.1% | 10.0% | 7.0% | 9.4% | 10.1% | 6.0% | 1.4% | 0.8% | -5.6% | -8.4% | -5.6% | -8.7% | |
GAAP Reported Revenue Growth — Reconciliation Table Rounded (% YoY)(%) | 8.0% | 10.0% | 7.0% | 9.0% | 10.0% | 6.0% | 1.0% | 1.0% | -6.0% | -8.0% | -6.0% | -9.0% | |
Non-GAAP Revenue Growth Excl. Acquisitions & Divestitures (% YoY)(%) | 8.0% | 10.0% | 7.0% | 8.0% | 8.0% | 4.0% | -5.0% | -8.0% | -5.0% | -9.0% | |||
Non-GAAP Core Revenue Excl. M&A ($M)($M) | 1,868 | 1,835 | 1,798 | 1,839 | 1,709 | 1,631 | 1,655 | 1,691 | 1,578 | 1,573 | 1,658 | 1,688 | |
Currency (FX) Impact on Revenue Growth (percentage points)(%) | 1.0% | 4.0% | 3.0% | 1.0% | 2.0% | -1.0% | -1.0% | 0.0% | -1.0% | -1.0% | 1.0% | 1.0% | |
Currency (FX) Impact on Revenue ($M)($M) | 4 | 61 | 44 | 15 | 35 | -25 | -22 | 9 | -18 | -14 | 16 | 20 | |
Ignite Strategic Pricing Contribution to Revenue Growth (bps)(bps) | 200 | 200 | 200 | 150 | |||||||||
Consecutive Quarters with Instrument Book-to-Bill Ratio ≥ 1.0 (quarters) | 10 | 9 | 8 | ||||||||||
Life Sciences & Diagnostics Markets Group (LDG) — Core Revenue Growth (% YoY)(%)5 | 10.0% | 9.0% | 3.0% | 11.0% | 7.0% | 3.0% | 1.0% | ||||||
LDG — GAAP Revenue Growth (% YoY)(%) | 11.0% | 12.0% | 5.0% | 15.0% | 14.0% | 8.0% | 4.0% | ||||||
LDG — Non-GAAP Revenue Growth Excl. M&A (% YoY)(%) | 10.0% | 12.0% | 5.0% | 12.0% | 9.0% | 2.0% | |||||||
LDG — Non-GAAP Core Revenue Excl. M&A ($M)($M) | 736 | 732 | 679 | 733 | 641 | 617 | 621 | ||||||
LDG — Currency (FX) Impact (percentage points)(%) | 0.0% | 3.0% | 2.0% | 1.0% | 2.0% | -1.0% | -1.0% | ||||||
LDG — Currency (FX) Impact ($M)($M) | 1 | 22 | 16 | 6 | 13 | -7 | -6 | ||||||
Agilent CrossLab Group (ACG) — Core Revenue Growth (% YoY)(%)4 | 5.0% | 2.0% | 6.0% | 6.0% | 5.0% | 9.0% | 3.0% | ||||||
ACG — GAAP Revenue Growth (% YoY)(%) | 6.0% | 6.0% | 9.0% | 7.0% | 8.0% | 7.0% | 1.0% | ||||||
ACG — Non-GAAP Revenue Growth Excl. M&A (% YoY)(%) | 6.0% | 6.0% | 9.0% | 7.0% | 8.0% | 7.0% | 1.0% | ||||||
ACG — Currency (FX) Impact (percentage points)(%) | 1.0% | 4.0% | 3.0% | 1.0% | 3.0% | -2.0% | -2.0% | ||||||
ACG — Currency (FX) Impact ($M)($M) | 2 | 29 | 20 | 7 | 16 | -13 | -11 | ||||||
Applied Markets Group (AMG) — Core Revenue Growth (% YoY)(%)4 | 7.0% | 11.0% | 4.0% | 3.0% | 5.0% | -2.0% | |||||||
AMG — GAAP Revenue Growth (% YoY)(%) | 7.0% | 14.0% | 7.0% | 4.0% | 7.0% | -1.0% | -4.0% | ||||||
AMG — Non-GAAP Revenue Growth Excl. M&A (% YoY)(%) | 7.0% | 14.0% | 7.0% | 4.0% | 7.0% | -1.0% | -4.0% | ||||||
AMG — Currency (FX) Impact (percentage points)(%) | 0.0% | 3.0% | 3.0% | 1.0% | 2.0% | -1.0% | -2.0% | ||||||
AMG — Currency (FX) Impact ($M)($M) | 1 | 10 | 8 | 2 | 6 | -5 | -5 | ||||||
Legacy Life Sciences & Applied Markets Group (LSAG, pre-FY2025) — Core Revenue Growth (% YoY)(%)11 | -1.0% | -7.0% | -13.0% | -11.0% | -18.0% | ||||||||
Legacy LSAG — GAAP Revenue Growth (% YoY)(%) | -1.0% | -8.0% | -14.0% | -10.0% | -17.0% | ||||||||
Legacy LSAG — Non-GAAP Core Revenue Excl. M&A ($M)($M) | 833 | 782 | 754 | 846 | 928 | ||||||||
Legacy LSAG — Currency (FX) Impact (percentage points)(%) | 0.0% | -1.0% | -1.0% | 1.0% | 1.0% | ||||||||
Legacy Diagnostics & Genomics Group (DGG, pre-FY2025) — Core Revenue Growth (% YoY)(%) | -3.0% | -8.0% | -8.0% | -6.0% | |||||||||
Legacy DGG — GAAP Revenue Growth (% YoY)(%) | -1.0% | -9.0% | -9.0% | -6.0% | 1.0% | ||||||||
Legacy DGG — Non-GAAP Core Revenue Excl. M&A ($M)($M) | 432 | 385 | 417 | 407 | 356 | ||||||||
Legacy DGG — Currency (FX) Impact (percentage points)(%) | 0.0% | 0.0% | 0.0% | 1.0% | 2.0% | ||||||||
Legacy Agilent CrossLab Group (ACG Pre-Recast, pre-FY2025) — Core Revenue Growth (% YoY)(%) | 5.0% | 5.0% | 5.0% | 5.0% | 4.0% | ||||||||
Legacy ACG (Pre-Recast) — GAAP Revenue Growth (% YoY)(%) | 5.0% | 4.0% | 4.0% | 6.0% | 6.0% | ||||||||
Legacy ACG (Pre-Recast) — Non-GAAP Core Revenue Excl. M&A ($M)($M) | 426 | 411 | 402 | 405 | 404 | ||||||||
Legacy ACG (Pre-Recast) — Currency (FX) Impact (percentage points)(%) | 0.0% | -1.0% | -1.0% | 1.0% | 2.0% | ||||||||
Pharmaceutical & Biopharma End Market — Revenue ($M)($M)2 | 707 | 663 | 640 | 690 | 629 | 603 | 585 | 595 | 540 | 542 | 565 | 590 | |
Pharmaceutical & Biopharma End Market — Core Revenue Growth (% YoY)(%) | 12.0% | 6.0% | 7.0% | 12.0% | 9.0% | 6.0% | 0.0% | -1.0% | -8.0% | -11.0% | -12.0% | ||
Pharmaceutical & Biopharma End Market — Share of Consolidated Revenue (%)(%) | 38.0% | 36.0% | 36.0% | 37.0% | 36.0% | 36.0% | |||||||
Chemicals & Advanced Materials End Market — Revenue ($M)($M)2 | 430 | 412 | 422 | 414 | 399 | 369 | 379 | 385 | 356 | 362 | 392 | 381 | |
Chemicals & Advanced Materials End Market — Core Revenue Growth (% YoY)(%) | 7.0% | 8.0% | 9.0% | 7.0% | 10.0% | 4.0% | -2.0% | 1.0% | -5.0% | -3.0% | -4.0% | ||
Chemicals & Advanced Materials End Market — Share of Consolidated Revenue (%)(%) | 23.0% | 23.0% | 23.0% | 22.0% | 23.0% | 22.0% | |||||||
Diagnostics & Clinical End Market — Revenue ($M)($M)2 | 284 | 295 | 263 | 276 | 258 | 255 | 240 | 255 | 242 | 239 | 228 | 236 | |
Diagnostics & Clinical End Market — Core Revenue Growth (% YoY)(%) | 6.0% | 11.0% | 7.0% | 7.0% | 4.0% | 8.0% | 7.0% | 7.0% | 2.0% | -2.0% | -5.0% | ||
Diagnostics & Clinical End Market — Share of Consolidated Revenue (%)(%) | 15.0% | 16.0% | 15.0% | 15.0% | 15.0% | 15.0% | |||||||
Environmental & Forensics End Market — Revenue ($M)($M)2 | 171 | 186 | 177 | 180 | 163 | 159 | 172 | 164 | 168 | 152 | 166 | 175 | |
Environmental & Forensics End Market — Core Revenue Growth (% YoY)(%) | 5.0% | 13.0% | 0.0% | 9.0% | -5.0% | 6.0% | 6.0% | -6.0% | 4.0% | -2.0% | -1.0% | ||
Environmental & Forensics End Market — Share of Consolidated Revenue (%)(%) | 9.0% | 10.0% | 10.0% | 10.0% | 9.0% | 10.0% | |||||||
Food End Market — Revenue ($M)($M)2 | 158 | 147 | 166 | 165 | 157 | 147 | 168 | 152 | 144 | 139 | 157 | 156 | |
Food End Market — Core Revenue Growth (% YoY)(%) | 0.0% | -3.0% | -4.0% | 7.0% | 7.0% | 8.0% | 9.0% | -3.0% | -3.0% | -13.0% | -3.0% | ||
Food End Market — Share of Consolidated Revenue (%)(%) | 8.0% | 8.0% | 9.0% | 9.0% | 9.0% | 9.0% | |||||||
Academia & Government End Market — Revenue ($M)($M)2 | 128 | 132 | 130 | 136 | 132 | 135 | 137 | 150 | 128 | 139 | 150 | 150 | |
Academia & Government End Market — Core Revenue Growth (% YoY)(%) | -3.0% | -5.0% | -8.0% | -10.0% | 1.0% | -2.0% | -7.0% | -1.0% | -11.0% | -12.0% | 2.0% | ||
Academia & Government End Market — Share of Consolidated Revenue (%)(%) | 7.0% | 7.0% | 7.0% | 7.0% | 8.0% | 8.0% | |||||||
Recurring Revenue: Consumables, Services & Informatics (Non-Instrumentation, $M)($M)2 | 1,235 | 1,217 | 1,140 | 1,208 | 1,139 | 1,118 | 1,056 | 1,081 | 1,022 | 1,025 | 1,028 | 1,037 | |
Recurring Revenue Share (Consumables, Services & Informatics, % of Total Revenue)(%) | 66.0% | 66.0% | 63.0% | 65.0% | 66.0% | 67.0% | |||||||
Instruments Revenue Share (% of Total Revenue)(%) | 34.0% | 34.0% | 37.0% | 35.0% | 34.0% | 33.0% | |||||||
Americas — Revenue ($M)($M)2 | 761 | 764 | 678 | 776 | 683 | 678 | 669 | 680 | 626 | 637 | 630 | 702 | |
Americas — Core Revenue Growth (% YoY)(%) | 10.0% | 11.0% | 1.0% | 11.0% | 5.0% | 2.0% | 3.0% | -6.0% | -5.0% | -8.0% | |||
Americas — Share of Consolidated Revenue (%)(%) | 40.0% | 42.0% | 38.0% | 42.0% | 39.0% | 41.0% | |||||||
Europe — Revenue ($M)($M)2 | 504 | 518 | 518 | 526 | 492 | 442 | 463 | 454 | 432 | 426 | 458 | 433 | |
Europe — Core Revenue Growth (% YoY)(%) | 2.0% | 8.0% | 4.0% | 11.0% | 7.0% | 6.0% | 2.0% | 0.0% | -3.0% | -4.0% | |||
Europe — Share of Consolidated Revenue (%)(%) | 27.0% | 28.0% | 29.0% | 28.0% | 28.0% | 26.0% | |||||||
Asia-Pacific — Revenue ($M)($M)3 | 613 | 553 | 602 | 559 | 563 | 548 | 549 | 567 | 520 | 510 | 570 | 553 | |
Asia-Pacific (Total) — Core Revenue Growth (% YoY)(%) | 9.0% | -1.0% | 9.0% | 0.0% | 7.0% | 10.0% | |||||||
Asia-Pacific — Share of Consolidated Revenue (%)(%) | 33.0% | 30.0% | 33.0% | 30.0% | 33.0% | 33.0% | |||||||
China — Core Revenue Growth (% YoY)(%) | 9.0% | -9.0% | 6.0% | -4.0% | 4.0% | 10.0% | 2.0% | -3.0% | -11.0% | -21.0% | -9.0% | ||
Life Sciences & Diagnostics Markets Group (LDG) — Segment Revenue ($M)($M)8 | 746 | 732 | 679 | 755 | 670 | 654 | 647 | 657 | 585 | 604 | 620 | 674 | |
Life Sciences & Diagnostics Markets Group (LDG) — Segment Gross Margin (%)(%) | 55.5% | 54.1% | 50.5% | 52.9% | 50.5% | 52.8% | 52.8% | 53.8% | 54.4% | 55.1% | 54.9% | 55.8% | |
Life Sciences & Diagnostics Markets Group (LDG) — Segment Operating Margin (%)(%) | 23.5% | 22.0% | 16.0% | 22.7% | 17.6% | 19.7% | 18.1% | 21.5% | 19.6% | 19.0% | 18.4% | 23.7% | |
Life Sciences & Diagnostics Markets Group (LDG) — Cost of Products and Services ($M, ASU 2023-07)($M) | 332 | 337 | 336 | 355 | 332 | 309 | 305 | ||||||
Life Sciences & Diagnostics Markets Group (LDG) — Research & Development Expense ($M, ASU 2023-07)($M) | 66 | 64 | 65 | 65 | 61 | 59 | 63 | 61 | 59 | 64 | 66 | 65 | |
Life Sciences & Diagnostics Markets Group (LDG) — Selling, General & Administrative Expense ($M, ASU 2023-07)($M) | 172 | 170 | 169 | 163 | 159 | 157 | 162 | 152 | 145 | 154 | 160 | 151 | |
Life Sciences & Diagnostics Markets Group (LDG) — Share-Based Compensation Expense ($M)($M) | 11 | 11 | 14 | 9 | 8 | 9 | 15 | ||||||
Life Sciences & Diagnostics Markets Group (LDG) — Depreciation Expense ($M)($M) | 24 | 26 | 26 | 25 | 25 | 24 | 23 | ||||||
Life Sciences & Diagnostics Markets Group (LDG) — Segment Goodwill Carrying Value ($M)($M) | 3,545 | 2,997 | 2,997 | 2,996 | 2,998 | 2,999 | 2,961 | 3,000 | 2,489 | ||||
Agilent CrossLab Group (ACG) — Segment Revenue ($M)($M)9 | 786 | 759 | 758 | 755 | 744 | 713 | 696 | 706 | 691 | 664 | 686 | 672 | |
Agilent CrossLab Group (ACG) — Segment Gross Margin (%)(%) | 57.0% | 55.5% | 55.2% | 54.9% | 55.1% | 55.5% | 56.1% | 56.3% | 57.7% | 56.6% | 56.9% | 55.8% | |
Agilent CrossLab Group (ACG) — Segment Income from Operations ($M)($M) | 270 | 242 | 240 | 246 | 248 | 231 | 221 | 239 | 248 | 216 | 222 | 220 | |
Agilent CrossLab Group (ACG) — Segment Operating Margin (%)(%) | 34.3% | 32.0% | 31.6% | 32.5% | 33.3% | 32.4% | 31.8% | 33.8% | 35.9% | 32.5% | 32.4% | 32.8% | |
Agilent CrossLab Group (ACG) — Cost of Products and Services ($M, ASU 2023-07)($M) | 338 | 338 | 340 | 340 | 334 | 317 | 306 | ||||||
Agilent CrossLab Group (ACG) — Research & Development Expense ($M, ASU 2023-07)($M) | 28 | 28 | 28 | 27 | 26 | 27 | 26 | 25 | 25 | 26 | 29 | 26 | |
Agilent CrossLab Group (ACG) — Selling, General & Administrative Expense ($M, ASU 2023-07)($M) | 150 | 151 | 150 | 142 | 136 | 138 | 143 | 133 | 126 | 134 | 139 | 129 | |
Agilent CrossLab Group (ACG) — Share-Based Compensation Expense ($M)($M) | 12 | 12 | 16 | 10 | 9 | 11 | 16 | ||||||
Agilent CrossLab Group (ACG) — Depreciation Expense ($M)($M) | 14 | 14 | 14 | 14 | 14 | 14 | 14 | ||||||
Agilent CrossLab Group (ACG) — Segment Goodwill Carrying Value ($M)($M) | 1,171 | 1,172 | 1,171 | 1,168 | 1,168 | 1,167 | 1,164 | 1,168 | 1,166 | ||||
Applied Markets Group (AMG) — Segment Revenue ($M)($M)8 | 346 | 344 | 361 | 351 | 324 | 301 | 338 | 338 | 302 | 305 | 352 | 342 | |
Applied Markets Group (AMG) — Segment Gross Margin (%)(%) | 57.3% | 55.8% | 56.5% | 54.6% | 53.6% | 53.5% | 55.8% | 55.0% | 55.2% | 54.2% | 56.4% | 55.7% | |
Applied Markets Group (AMG) — Segment Operating Margin (%)(%) | 24.9% | 23.3% | 25.8% | 24.7% | 21.8% | 19.5% | 25.0% | 25.3% | 23.2% | 21.0% | 26.1% | 25.9% | |
Applied Markets Group (AMG) — Cost of Products and Services ($M, ASU 2023-07)($M) | 148 | 152 | 157 | 159 | 150 | 140 | 150 | ||||||
Applied Markets Group (AMG) — Research & Development Expense ($M, ASU 2023-07)($M) | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 23 | 23 | 23 | 25 | 25 | |
Applied Markets Group (AMG) — Selling, General & Administrative Expense ($M, ASU 2023-07)($M) | 88 | 88 | 87 | 81 | 80 | 79 | 81 | 77 | 74 | 78 | 82 | 77 | |
Applied Markets Group (AMG) — Share-Based Compensation Expense ($M)($M) | 5 | 6 | 7 | 4 | 4 | 5 | 8 | ||||||
Applied Markets Group (AMG) — Depreciation Expense ($M)($M) | 6 | 7 | 6 | 7 | 6 | 6 | 6 | ||||||
Applied Markets Group (AMG) — Segment Goodwill Carrying Value ($M)($M) | 314 | 315 | 316 | 309 | 309 | 308 | 304 | 309 | 305 | ||||
Total Reportable Segments Income from Operations ($M)($M)3 | 532 | 483 | 442 | 505 | 437 | 419 | 422 | 466 | 432 | 395 | 428 | ||
Unallocated Corporate Expense: Amortization of Intangible Assets ($M)($M) | 21 | 19 | 19 | 23 | 26 | 27 | 28 | 25 | 25 | 26 | 26 | 27 | |
Unallocated Corporate Expense: Acquisition & Integration Costs ($M)($M) | 7 | 12 | 3 | 4 | 3 | 3 | 9 | 7 | 4 | 1 | 2 | 4 | |
Unallocated Corporate Expense: Transformational Initiatives & Other ($M)($M) | 8 | 6 | 28 | 6 | 13 | 9 | 2 | 15 | 2 | 5 | 2 | -9 | |
Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M)($M)2 | 833 | 782 | 754 | 846 | 839 | ||||||||
Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Gross Margin (%)(%) | 59.1% | 60.2% | 59.4% | 60.2% | 59.5% | ||||||||
Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Operating Margin (%)(%) | 28.0% | 28.4% | 24.7% | 27.9% | 28.6% | ||||||||
Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M)($M)2 | 442 | 385 | 417 | 407 | 445 | ||||||||
Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Gross Margin (%)(%) | 51.5% | 51.8% | 53.7% | 52.8% | 53.7% | ||||||||
Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Operating Margin (%)(%) | 21.2% | 18.3% | 20.5% | 17.3% | 22.7% | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M)($M)6 | 426 | 411 | 402 | 405 | 404 | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Gross Margin (%)(%) | 50.9% | 52.1% | 50.2% | 50.5% | 50.4% | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Income from Operations ($M)($M) | 139 | 140 | 123 | 122 | 128 | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Operating Margin (%)(%) | 32.6% | 34.0% | 30.5% | 30.2% | 31.7% | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Americas Revenue ($M, 2D Segment × Region)($M) | 173 | 170 | 167 | 164 | 167 | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Europe Revenue ($M, 2D Segment × Region)($M) | 117 | 113 | 111 | 111 | 108 | ||||||||
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Asia-Pacific Revenue ($M, 2D Segment × Region)($M) | 136 | 128 | 124 | 130 | 129 | ||||||||
Remaining Performance Obligations (RPO on Contracts > 1 Year, $M)($M)6 | 434 | 433 | 459 | 437 | 425 | 429 | 408 | 409 | 344 | 340 | 344 | 331 | |
Total Contract Liabilities (Current & Long-Term Deferred Revenue, $M)($M) | 822 | 855 | 877 | 803 | 800 | 810 | 782 | 701 | 646 | 654 | 644 | 616 | |
Current Deferred Revenue (Short-Term Contract Liabilities, $M)($M) | 640 | 665 | 682 | 624 | 620 | 628 | 612 | 544 | 524 | 533 | 522 | 505 | |
Contract Liabilities Rollforward: Net Revenue Deferred in the Period ($M)($M) | 67 | 130 | 301 | 58 | 74 | 120 | 312 | 13 | 63 | 139 | 254 | 50 | |
Contract Liabilities Rollforward: Revenue Recognized from Beginning Balance ($M)($M) | 101 | 136 | 250 | 47 | 82 | 117 | 230 | 26 | 72 | 121 | 229 | 41 | |
Contract Liabilities Rollforward: Change in Deferrals from Customer Cash Advances ($M)($M) | 8 | -11 | 10 | -6 | -3 | 2 | 14 | -1 | -2 | -1 | -5 | -4 | |
Contract Assets (Unbilled Accounts Receivable, $M)($M) | 316 | 326 | 286 | 329 | 294 | 289 | 248 | 247 | 244 | 242 | 239 | 252 | |
Non-GAAP Net Income ($M)($M)11 | 459 | 423 | 386 | 452 | 390 | 373 | 377 | 418 | 385 | 356 | 380 | 404 | |
Non-GAAP Diluted EPS ($)($) | 1.62 | 1.49 | 1.36 | 1.59 | 1.37 | 1.31 | 1.31 | 1.46 | 1.32 | 1.22 | 1.29 | 1.38 | |
Non-GAAP Gross Margin (%)(%) | 56.4% | 55.0% | 53.7% | 54.1% | 53.1% | 54.1% | 54.7% | 55.1% | 56.0% | 55.6% | 56.0% | ||
Non-GAAP Operating Margin (%)(%) | 28.3% | 26.4% | 24.6% | 27.2% | 25.1% | 25.1% | 25.1% | 27.4% | 27.4% | 25.1% | 25.8% | ||
Non-GAAP Effective Tax Rate (%)(%) | 14.5% | 14.5% | 14.5% | 12.0% | 12.0% | 11.5% | 12.5% | 11.2% | 13.0% | 12.5% | 13.5% | 13.8% | |
Net Leverage Ratio (Net Debt / Adjusted EBITDA, x)(×) | 1.00 | 0.70 | 0.80 | 0.80 | 0.90 | 1.00 | 1.00 | 1.10 | 0.60 | ||||
Non-GAAP Adjustment: Amortization of Intangible Assets ($M)($M) | 21 | 19 | 19 | 23 | 26 | 27 | 28 | 25 | 25 | 26 | 26 | 27 | |
Non-GAAP Adjustment: Transformational Initiatives ($M)($M) | 37 | 39 | 19 | 21 | 18 | 24 | 6 | 6 | 1 | 1 | 3 | -6 | |
Non-GAAP Adjustment: Restructuring & Workplace Optimization ($M)($M) | 15 | 8 | 20 | 8 | 17 | 56 | 1 | 5 | 67 | 1 | 3 | 46 | |
Non-GAAP Adjustment: Acquisition & Integration Costs ($M)($M) | 7 | 12 | 3 | 4 | 3 | 3 | 9 | 7 | 4 | -1 | 2 | 4 | |
Non-GAAP Adjustment: Other Non-GAAP Costs ($M)($M) | 8 | 7 | 27 | 5 | 12 | 9 | 6 | 13 | 3 | 7 | -6 | -11 | |
Non-GAAP Adjustment: Tax Effect of Non-GAAP Adjustments ($M)($M) | 4 | -2 | -7 | -55 | -23 | -3 | -5 | -3 | 4 | 15 | -4 | -119 | |
Total Inventories, Net ($M)($M)3 | 1,117 | 1,089 | 1,059 | 1,025 | 1,014 | 991 | 997 | 972 | 978 | 1,000 | 1,033 | 1,031 | |
Finished Goods Inventory ($M)($M) | 581 | 561 | 546 | 547 | 544 | 529 | 532 | 523 | 538 | 551 | 569 | 570 | |
Purchased Parts, Raw Materials & Work-in-Process Inventory ($M)($M) | 536 | 528 | 513 | 478 | 470 | 462 | 465 | 449 | 440 | 449 | 464 | 461 | |
Inventory Charges for Excess & Obsolete Inventory ($M)($M) | 10 | 15 | 10 | 15 | 8 | 12 | 10 | 12 | 10 | 12 | 11 | 13 | |
Total Gross Amortizable Intangible Assets ($M)($M)5 | 906 | 407 | 426 | 445 | 469 | 495 | 514 | 547 | 392 | 417 | 443 | 475 | |
Developed Technology — Gross Carrying Amount ($M)($M) | 364 | 229 | 239 | 249 | 263 | 279 | 296 | 315 | 325 | 342 | 360 | 374 | |
Customer Relationships — Gross Carrying Amount ($M)($M) | 512 | 149 | 154 | 160 | 167 | 174 | 173 | 184 | 28 | 31 | 34 | 37 | |
Third-Party Technology & Licenses — Gross Carrying Amount ($M)($M) | 8 | 8 | 10 | 11 | 12 | 13 | 14 | 14 | 16 | 18 | 19 | 21 | |
Trademarks & Trade Names — Gross Carrying Amount ($M)($M) | 16 | 15 | 16 | 18 | 20 | 21 | 23 | 25 | 23 | 26 | 30 | 33 | |
Order & Production Backlog — Gross Carrying Amount ($M)($M) | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | |||||
FDA 510(k) Premarket Clearances — Agilent Technologies & Dako (clearances)3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
FDA Premarket Approvals (PMA & Supplements) — Agilent Technologies & Dako (approvals) | 1 | 3 | 1 | 2 | 3 | 4 | 0 | 2 | 0 | 0 | 1 | 0 | |
FDA 510(k) Premarket Clearances — U.S. Medical Device Industry Total (clearances) | 889 | 835 | 736 | 823 | 882 | 767 | 812 | 814 | 793 | 750 | 780 | 941 | |
FDA Premarket Approvals (PMA & Supplements) — U.S. Medical Device Industry Total (approvals) | 616 | 641 | 434 | 613 | 597 | 564 | 607 | 569 | 575 | 486 | 582 | 600 | |
FDA MAUDE Adverse Event Reports — Agilent Technologies & Dako Total (reports)6 | 3 | 1 | 3 | 6 | 10 | 27 | 26 | 19 | 19 | 22 | 25 | 8 | |
FDA MAUDE Device Malfunction Reports — Agilent Technologies & Dako (reports) | 2 | 1 | 3 | 6 | 10 | 27 | 26 | 18 | 19 | 22 | 25 | 8 | |
FDA MAUDE Injury Reports — Agilent Technologies & Dako (reports) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
FDA MAUDE Death Reports — Agilent Technologies & Dako (reports) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
FDA Medical Device Recalls — Agilent Technologies & Dako (recalls) | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |
FDA Device Enforcement Actions — Agilent Technologies & Dako (actions) | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | |
FDA MAUDE Adverse Event Reports — U.S. Medical Device Industry Total (reports) | 963,661 | 824,539 | 784,473 | 760,623 | 743,346 | 650,998 | 704,375 | 705,389 | 660,962 | 598,054 | 575,423 | 611,520 | |
BLS Producer Price Index: Analytical Laboratory Instrument Manufacturing (NAICS 334516, Index)(×)5 | 203.60 | 203.60 | 202.00 | 196.10 | 195.80 | 195.20 | 195.30 | 191.60 | 191.70 | 191.60 | 188.80 | 186.80 | |
BLS Producer Price Index: In-Vitro Diagnostic Substance Manufacturing (NAICS 325413, Index)(×) | 300.60 | 303.80 | 305.00 | 300.30 | 298.20 | 297.10 | 292.20 | 284.50 | 284.50 | 284.70 | 286.10 | 281.00 | |
BLS Producer Price Index: Pharmaceutical Preparation Manufacturing (NAICS 325412, Index)(×) | 928.80 | 926.50 | 924.20 | 918.60 | 915.20 | 916.00 | 913.60 | 917.90 | 915.40 | 914.70 | 905.90 | 896.20 | |
BLS Producer Price Index: Electromedical & Electrotherapeutic Apparatus (NAICS 334510, Index)(×) | 92.80 | 92.00 | 91.90 | 91.60 | 90.30 | 90.10 | 90.00 | 89.50 | 89.20 | 88.40 | 88.00 | 87.80 | |
BLS Producer Price Index: Surgical & Medical Instrument Manufacturing (NAICS 339112, Index)(×) | 163.20 | 161.90 | 161.70 | 159.50 | 157.00 | 156.50 | 157.20 | 155.30 | 154.50 | 153.80 | 153.30 | 150.80 | |
U.S. Census QSS: General Medical & Surgical Hospitals Revenue ($M)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Consolidated Net Revenue ($M)($M)14 | 1,878 | 1,835 | 1,798 | 1,861 | 1,738 | 1,668 | 1,681 | 1,701 | 1,578 | 1,573 | 1,658 | 1,688 | |
Consolidated Cost of Products and Services ($M)($M) | 836 | 845 | 852 | 871 | 850 | 802 | 782 | 785 | 723 | 717 | 750 | 773 | |
Consolidated Research & Development Expense ($M)($M) | 123 | 126 | 117 | 119 | 111 | 112 | 113 | 111 | 127 | 113 | 128 | 114 | |
Consolidated Selling, General & Administrative Expense ($M)($M) | 475 | 465 | 476 | 428 | 417 | 454 | 410 | 397 | 395 | 380 | 396 | 393 | |
Total Costs and Expenses ($M)($M) | 1,434 | 1,436 | 1,445 | 1,418 | 1,378 | 1,368 | 1,305 | 1,293 | 1,245 | 1,210 | 1,274 | 1,280 | |
Consolidated Income from Operations ($M)($M) | 444 | 399 | 353 | 443 | 360 | 300 | 376 | 408 | 333 | 363 | 384 | 408 | |
Interest Income ($M)($M) | 15 | 13 | 15 | 17 | 16 | 14 | 15 | 24 | 19 | 19 | 18 | 17 | |
Interest Expense ($M)($M) | 29 | 25 | 25 | 27 | 28 | 29 | 28 | 32 | 22 | 20 | 22 | 22 | |
Other Income (Expense), Net ($M)($M) | 14 | 21 | 21 | 9 | 18 | -25 | 4 | 1 | 13 | 12 | 23 | 17 | |
Income Before Taxes ($M)($M) | 444 | 408 | 364 | 442 | 366 | 260 | 367 | 401 | 343 | 374 | 403 | 420 | |
Provision for Income Taxes ($M)($M) | 82 | 69 | 59 | 8 | 30 | 45 | 49 | 50 | 61 | 66 | 55 | -55 | |
GAAP Net Income ($M)($M) | 362 | 339 | 305 | 434 | 336 | 215 | 318 | 351 | 282 | 308 | 348 | 475 | |
GAAP Basic EPS ($)($) | 1.28 | 1.20 | 1.08 | 1.18 | 0.75 | 1.12 | 0.97 | 1.05 | 1.19 | ||||
GAAP Diluted EPS ($)($) | 1.28 | 1.20 | 1.07 | 1.18 | 0.75 | 1.11 | 0.97 | 1.05 | 1.18 | ||||
Cash Dividends Declared per Share ($)($) | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.25 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 | 0.23 | |
Consolidated Total Assets ($M)($M)12 | 13,967 | 13,065 | 12,813 | 12,727 | 12,226 | 12,158 | 11,914 | 11,846 | 10,996 | 10,856 | 10,948 | 10,763 | |
Cash and Cash Equivalents ($M)($M) | 1,758 | 1,807 | 1,758 | 1,789 | 1,537 | 1,489 | 1,470 | 1,332 | 1,782 | 1,674 | 1,750 | 1,590 | |
Accounts Receivable, Net ($M)($M) | 1,478 | 1,498 | 1,521 | 1,487 | 1,382 | 1,366 | 1,328 | 1,324 | 1,227 | 1,249 | 1,295 | 1,291 | |
Inventories, Net ($M)($M) | 1,117 | 1,089 | 1,059 | 1,025 | 1,014 | 991 | 997 | 972 | 978 | 1,000 | 1,033 | 1,031 | |
Property, Plant and Equipment, Net ($M)($M) | 2,134 | 2,099 | 2,078 | 2,023 | 1,966 | 1,912 | 1,816 | 1,778 | 1,446 | 1,371 | 1,314 | 1,270 | |
Goodwill ($M)($M) | 5,030 | 4,484 | 4,484 | 4,473 | 4,475 | 4,474 | 4,429 | 4,477 | 3,965 | 3,963 | 3,967 | 3,960 | |
Other Intangible Assets, Net ($M)($M) | 906 | 407 | 426 | 445 | 469 | 495 | 514 | 547 | 392 | 417 | 443 | 475 | |
Operating Lease Right-of-Use Assets ($M)($M) | 187 | 181 | 189 | 183 | 179 | 182 | 172 | 177 | 178 | 162 | 155 | 154 | |
Short-Term Debt & Current Portion of Long-Term Debt ($M)($M) | 304 | 304 | 304 | 304 | 59 | 146 | 16 | 45 | 795 | 420 | 0 | ||
Operating Lease Liabilities ($M)($M) | 199 | 187 | 196 | 189 | 185 | 189 | 177 | 184 | 184 | 170 | 164 | 164 | |
Consolidated Total Liabilities ($M)($M) | 6,604 | 5,943 | 5,905 | 5,986 | 5,856 | 6,022 | 5,887 | 5,948 | 5,093 | 4,642 | 4,760 | 4,918 | |
Total Stockholders' Equity ($M)($M) | 7,363 | 7,122 | 6,908 | 6,741 | 6,370 | 6,136 | 6,027 | 5,898 | 5,903 | 6,214 | 6,188 | 5,845 | |
Common Shares Outstanding (Millions)(M) | 282 | 282 | 283 | 283 | 284 | 284 | 285 | 285 | 288 | 292 | 293 | 292 | |
Operating Cash Flow ($M)($M)5 | 519 | 277 | 268 | 545 | 362 | 221 | 431 | 481 | 452 | 333 | 485 | 516 | |
Capital Expenditures ($M)($M) | 80 | 76 | 93 | 93 | 103 | 114 | 97 | 93 | 92 | 103 | 90 | 84 | |
Depreciation and Amortization ($M)($M) | 66 | 67 | 67 | 71 | 72 | 73 | 72 | 69 | 63 | 63 | 62 | 62 | |
Cash Dividends Paid ($M)($M) | 72 | 72 | 72 | 70 | 71 | 70 | 71 | 68 | 68 | 69 | 69 | 66 | |
Common Stock Repurchases ($M)($M) | 78 | 65 | 152 | 85 | 85 | 165 | 90 | 335 | 585 | 230 | 0 | 80 | |
Acquisitions, Net of Cash Acquired ($M)($M) | 950 | 0 | 0 | 0 | 0 | 0 | -4 | 859 | 3 | 0 | 0 | 0 | |
5 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Revenue Growth (Group 1) is Agilent's primary operational performance indicator, measuring constant-currency revenue growth excluding acquisitions and divestitures within the first 12 months post-closing.
- Effective Q1 FY2025 (three months ended January 31, 2025), Agilent reorganized its operating segments from LSAG, DGG, and ACG into Life Sciences & Diagnostics Markets Group (LDG), Agilent CrossLab Group (ACG), and Applied Markets Group (AMG). Recast quarterly and annual segment figures for FY2022–FY2024 are sourced from Form 8-K filed December 13, 2024, while legacy segment series through Q4 FY2024 are preserved in dedicated legacy rows.
- Allowed period derivations: Fourth-quarter flow figures not separately tabulated in 10-K filings (such as Note 4 End-Market revenue, Product-Type revenue, 2D Segment × Geography revenue, and Note 22 ASU 2023-07 segment expenses) are derived as Q4 = Full Year (10-K) − Nine Months (10-Q) from matching reporting bases. Quarterly cash flow statement figures for Q2–Q4 are derived from cumulative year-to-date filings (6M − Q1, 9M − 6M, FY − 9M).
- Consolidated minus standalone parent-only disaggregation does not apply because Agilent reports solely on a consolidated basis under U.S. GAAP and does not publish standalone parent-company financial statements.
Không hiện vì thiếu các kỳ gần đây (12)
- Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — R&D Expense ($M)
- Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — SG&A Expense ($M)
- Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — R&D Expense ($M)
- Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — SG&A Expense ($M)
- Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — R&D Expense ($M)
- Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — SG&A Expense ($M)
- Non-GAAP Net Income ($M) › Non-GAAP Adjustment: Asset Impairments ($M)
- Non-GAAP Net Income ($M) › Non-GAAP Adjustment: (Gain) Loss on Equity Securities ($M)
- Consolidated Total Assets ($M) › Long-Term Debt ($M)
- Legacy Chemical Analysis Segment Revenue (discontinued after FY2014, $M)
- Legacy Electronic Measurement / Keysight Segment Revenue (spun off in FY2015, $M)
- Legacy Life Sciences Segment Revenue (reorganized in FY2015, $M)
Dữ liệu cập nhật 2026-11-08.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
1. Core Revenue Growth & Organic Revenue Bridge
- Core Revenue Growth — Constant Currency, Excl. M&A (Headline Exact, % YoY) (%)23 kỳ
- Life Sciences & Diagnostics Markets Group (LDG) — Core Revenue Growth (% YoY) (%)7 kỳ
- Agilent CrossLab Group (ACG) — Core Revenue Growth (% YoY) (%)7 kỳ
- Applied Markets Group (AMG) — Core Revenue Growth (% YoY) (%)6 kỳ
- Legacy Life Sciences & Applied Markets Group (LSAG, pre-FY2025) — Core Revenue Growth (% YoY) (%)16 kỳ
2. End-Market Performance (6 End Markets) & Recurring Revenue Mix
- Pharmaceutical & Biopharma End Market — Revenue ($M) ($M)31 kỳ
- Chemicals & Advanced Materials End Market — Revenue ($M) ($M)31 kỳ
- Diagnostics & Clinical End Market — Revenue ($M) ($M)31 kỳ
- Environmental & Forensics End Market — Revenue ($M) ($M)31 kỳ
- Food End Market — Revenue ($M) ($M)31 kỳ
- Academia & Government End Market — Revenue ($M) ($M)31 kỳ
- Recurring Revenue: Consumables, Services & Informatics (Non-Instrumentation, $M) ($M)31 kỳ
3. Geographic Revenue, Regional Core Growth & Long-Lived Assets
4. Operating Segments — Managerial P&L, Expense Disaggregation & Region Matrix
- Life Sciences & Diagnostics Markets Group (LDG) — Segment Revenue ($M) ($M)19 kỳ
- Agilent CrossLab Group (ACG) — Segment Revenue ($M) ($M)19 kỳ
- Applied Markets Group (AMG) — Segment Revenue ($M) ($M)19 kỳ
- Total Reportable Segments Income from Operations ($M) ($M)30 kỳ
- Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M) ($M)24 kỳ
- Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M) ($M)24 kỳ
- Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M) ($M)24 kỳ
5. Remaining Performance Obligations (RPO) & Contract Balances Rollforward
6. Non-GAAP Profitability, Balance Sheet Breakdown & Lease Commitments
7. Facilities Footprint, Global Workforce, Pay Ratio & Auditor Fees
8. Sustainability, Environmental Footprint, Safety & 3TG Supply Chain
9. Subsidiary Statutory Filings — Agilent Technologies LDA UK Limited
10. External Regulatory & Industry Benchmarks (U.S. FDA & BLS / Census)
11. Consolidated Financial Statements & Segment Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Agilent Technologies
- SEC 10-Q (FY2026Q3, filed 2026-09-01, acc 0001090872-26-000064) ↗
- SEC 10-K (FY2025, filed 2025-12-22, acc 0001090872-25-000087) ↗
- SEC 10-K (FY2024, filed 2024-12-20, acc 0001090872-24-000049) ↗
- SEC 8-K (EX-99.1) (FY2026Q3, filed 2026-08-26, acc 0001090872-26-000062) ↗
- SEC 8-K (EX-99.1) (FY2025Q4, filed 2025-11-24, acc 0001090872-25-000070) ↗
- Agilent 2024 ESG Report (FY2024) ↗
- U.S. FDA 510(k) Premarket Notifications Database (openFDA API — Agilent Technologies & Dako) ↗
- U.S. FDA MAUDE Adverse Event Reports Database (openFDA API — Agilent Technologies & Dako Total) ↗
- U.S. Bureau of Labor Statistics / FRED Producer Price Index: Analytical Laboratory Instrument Manufacturing (PCU334516334516) ↗
- SEC 10-Q (filed 2026-09-01, acc 0001090872-26-000064) ↗
- SEC 10-K (filed 2025-12-22, acc 0001090872-25-000087) ↗
- SEC 8-K (EX-99.1) (FY2024Q4, filed 2024-11-25, acc 0001090872-24-000042) ↗
See a number that looks wrong?